Destiny Pharma is a clinical stage, biotechnology company focused on the development of novel medicines for the treatment of infectious diseases. The Company aims to develop new drugs for the prevention and treatment of life-threatening infections caused by antibiotic resistant bacteria, popularly referred to as superbugs. The need to develop medicines that combat antimicrobial resistant bacteria (AMR) is a medical priority highlighted by authorities including the FDA and the WHO.

Gauging the outcome of clinical trials requires the prospective investor to consider not just the clinical research done to this point, but to also assess the individuals responsible for developing the product and company. The purpose of this report is to present the facts of the matter in an objective manner to aid the reader in deriving their own informed judgement on Destiny Pharma’s prospects.